TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
ProPharma Group Sweden AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
55,651
|
64,349
|
65,115 |
| Financial expenses |
957
|
971
|
9 |
| Earnings before taxes |
-13,356
|
-2,458
|
-3,329 |
| EBITDA |
-12,351
|
-2,857
|
-3,204 |
| Total assets |
32,474
|
44,708
|
35,153 |
| Current assets |
32,207
|
44,355
|
34,705 |
| Current liabilities |
21,060
|
29,834
|
17,909 |
| Equity capital |
11,414
|
13,101
|
15,039 |
| - share capital |
65
|
67
|
67 |
| Employees (average) |
55
|
57
|
65 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
35.1%
|
29.3%
|
42.8% |
| Turnover per employee |
1,012
|
1,129
|
1,002 |
| Profit as a percentage of turnover |
-24.0%
|
-3.8%
|
-5.1% |
| Return on assets (ROA) |
-38.2%
|
-3.3%
|
-9.4% |
| Current ratio |
152.9%
|
148.7%
|
193.8% |
| Return on equity (ROE) |
-117.0%
|
-18.8%
|
-22.1% |
| Change turnover |
-6,570
|
-1,102
|
422 |
| Change turnover % |
-11%
|
-2%
|
1% |
| Chg. No. of employees |
-2
|
-8
|
8 |
| Chg. No. of employees % |
-4%
|
-12%
|
14% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.